EMEA Office
Louizalaan 489
1050 Brussels
Belgium
A practical guide for quality and compliance leaders in life sciences navigating the FDA’s March 2026 draft guidance on Form 483 responses. Learn what the FDA now expects from investigations, CAPAs, executive oversight, effectiveness checks, and quality system remediation.
The FDA’s new draft guidance changes what an acceptable Form 483 response looks like. This guide breaks down what the new expectations mean in practice and how quality and compliance teams can strengthen inspection readiness before the next FDA inspection.
This FDA readiness scorecard includes:
EMEA Office
Louizalaan 489
1050 Brussels
Belgium
US Office
Scilife Inc.
228 E 45th St. RM 9E
New York, NY 10017
PRODUCT
RESOURCES
COMPANY
Contact Us
EMEA Office
Louizalaan 489
1050 Brussels
Belgium
US Office
Scilife Inc.
228 E 45th St. RM 9E
New York, NY 10017
Copyright 2026 Scilife N.V. All rights reserved.